ChemicalBook >> CAS DataBase List >>BTK inhibitor 17

BTK inhibitor 17

CAS No.
1858206-76-4
Chemical Name:
BTK inhibitor 17
Synonyms
BTK inhibitor 17;7H-Pyrazolo[3,4-d]pyridazin-7-one, 4-amino-1,6-dihydro-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-3-(4-phenoxyphenyl)-;BTK inhibitor17,oral,BTK inhibitor 17,Btk,rheumatoid,Inhibitor,inhibit,Cys481,Bruton tyrosine kinase,arthritis,BTK inhibitor-17
CBNumber:
CB08186702
Molecular Formula:
C25H24N6O3
Molecular Weight:
456.5
MDL Number:
MFCD34167515
MOL File:
1858206-76-4.mol
Last updated:2023-09-04 15:51:00

BTK inhibitor 17 Properties

Density 1.40±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 100 mg/mL (219.06 mM; Need ultrasonic)
pka 8.00±0.40(Predicted)

BTK inhibitor 17 Chemical Properties,Uses,Production

Biological Activity

BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research[1]. BTK inhibitor 17 (compound 8) could covalently bind to Cys481 and formed an HB network with hinge key residues Met477, Glu475, and gatekeeper Thr474[1]. BTK inhibitor 17 (compound 8; 3-10 mg/kg; oral gavage; daily; for 28 days) treatment inhibits the significant progression of the disease and exhibits a clear dose-dependent reduction per paw clinical scores, and no significant body weight loss is observed for all different dosages[1].BTK inhibitor 17 (compound 8) shows >95% plasma protein binding across three species of human, rat, and mouse. After an intravenous injection, the half-life (rat, 0.32 h; mice, 0.42 h), clearance (rat, 54.6 mL/min/kg; mice, 31.3 mL/min/kg), volume of distribution (rat, 1.55 L/kg; mice, 0.82 L/kg), and AUC exposure (rat, 604 ng.h/mL; mice, 576 ng.h/mL) are observed in two species. After oral administration, BTK inhibitor 17 exhibits higher Cmax (rat, 466 ng/mL; mice, 252 ng/mL) and plasma exposure (rat, 642 ng.h/mL; mice, 128 ng.h/mL) with a favorable oral bioavailability (rat, 23.7%; mice, 11.2%)[1].

References

[1]. Xuejun Zhang, et al. Discovery and Evaluation of Pyrazolo[3,4- d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. ACS Med Chem Lett. 2019 Dec 11;11(10):1863-1868.

BTK inhibitor 17 Preparation Products And Raw materials

Raw materials

Preparation Products

BTK inhibitor 17 Suppliers

Global( 14)Suppliers
Supplier Tel Email Country ProdList Advantage
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10523 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6393 58
TargetMol Chemicals Inc.
+1-781-999-5354 support@targetmol.com United States 19973 58
Hebei Miaoyin Technology Co.,Ltd
+86-17367732028 +86-17367732028 kathy@hbyinsheng.com China 3582 58
Aladdin Scientific
+1-833-552-7181 sales@aladdinsci.com United States 52927 58
Jiangsu shring Biopharma Co., Ltd. +8613372282299 sales@shringchem.com China 3545 58
Chuzhou KeMail Chemical Technology Co., Ltd 0550-5196001 15000891977 wj520wjxby@126.com China 1836 55
Sichuan Wei Keqi Biological Technology Co., Ltd. 028-81700200 18116577057 3003855609@qq.com China 7892 56
InvivoChem 13549236410 sales@invivochem.cn China 6713 58
TargetMol Chemicals Inc. 4008200310 marketing@tsbiochem.com China 24018 58
7H-Pyrazolo[3,4-d]pyridazin-7-one, 4-amino-1,6-dihydro-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-3-(4-phenoxyphenyl)- BTK inhibitor 17 BTK inhibitor17,oral,BTK inhibitor 17,Btk,rheumatoid,Inhibitor,inhibit,Cys481,Bruton tyrosine kinase,arthritis,BTK inhibitor-17 1858206-76-4